English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Vascular access (VA) thrombosis is complex and usually associated to a variable degree of stenosis. Only 30% of stenosis involving > 50% vessel area may result in thrombosis1. Percutaneous transluminal angioplasty (PTA) may promote hyperplasia, resulting in restenosis1,2. In 20% of grafts, the restenosis occurs after one week and in 40% after one month3. The drug-eluting balloon (DEB) delivers an antiproliferative drug –paclitaxel (+/2μg/mm2), in single short inflation. The primary objective of using DEB is to delay or inhibit the development of hyperplasia which will lead to restenosis.

A cost-effective analysis of drug-eluting balloon in highly recurrent stenosis on dialysis vascular access